Search results for " braf"
showing 4 items of 14 documents
CASO CLINICO: CARCINOMA TIROIDEO ASSOCIATO A IPERTIROIDISMO IN ETÀ PEDIATRICA: UNA RARA ASSOCIAZIONE
2019
PRESENTAZIONE DEL CASO, STORIA CLINICA E SINTOMATOLOGIA R, 8 anni, sesso femminile. Nulla di rilevante all’anamnesi fisiologica e patologica remota. Bimba in sovrappeso (BMI 24,65 Kg/m2). Familiarità per neoplasia tiroidea (zia materna), tiroidite di Hashimoto e per neoplasie di altri organi. Un mese prima, tonsillite essudativa trattata con terapia antibiotica; simultaneamente comparsa di tumefazione laterocervicale dx non dolente; insorgenza di dolore e progressivo incremento del volume della tumefazione per veniva condotta in PS; all’EO: aspetto non sofferente, tumefazione laterocervicale di consistenza parenchimatosa dura, mobile nei piani sopra e sottostanti; linfoadenopatie multiple i…
The Histone Deacetylase Inhibitor ITF2357 (Givinostat) Targets Oncogenic BRAF in Melanoma Cells and Promotes a Switch from Pro-Survival Autophagy to …
2022
Histone deacetylase inhibitors (HDACI) are epigenetic compounds that have been widely considered very promising antitumor agents. Here, we focus on the effects of the pan-HDAC inhibitor ITF2357 (Givinostat) in comparison with SAHA (Vorinostat) in melanoma cells bearing BRAF V600E oncogenic mutation. Our results indicate both ITF2357 and SAHA dose-dependently reduce the viability of BRAF-mutated SK-MEL-28 and A375 melanoma cells. The comparison of IC50 values revealed that ITF2357 was much more effective than SAHA. Interestingly, both inhibitors markedly decreased oncogenic BRAF protein expression levels, ITF2357 being the most effective compound. Moreover, the BRAF decrease induced by ITF23…
Diferenciācijas indukcijas izpēte pēc BRAF un mTOR inhibitoru apstrādes BRAF mutētās ādas melanomas šūnās
2022
Darba mērķis bija padziļināti izpētīt BRAF inhibīcijas un sekojoši kombinētās BRAF un mTOR inhiibīcijas ietkemi uz metastātiskās BRAF mutēās melanomas šūnu līnijas SKMel28 šūnu ciklu, dzīvotspēju un inducēto atgriezensiko epitelilālo diferenciāciju. Ar advancētām mikroskopijas un šūnu analīzes metodēm tika apskatīti šos procesus iespējami ietkmējošie mehānismi. BRAF inhibīcija ar Vemurafenib rezultējās melanomas šūnu epiteliālā diferenciācijā un G1 arestā. Kombinētā BRAF un mTOR inhibīcija šūnās pagarināja šūnu diferencētā fenotipa stadiju, kas norāda uz iespējamu PI3K ceļa iesaisti SKMel28 šūnu augšanas un proliferācijas procesos. Lai arī pēc kombinētās BRAF-mTOR inhibīcijas diferencētais …
Oncogenic BRAF and p53 Interplay in Melanoma Cells and the Effects of the HDAC Inhibitor ITF2357 (Givinostat)
2023
Oncogenic BRAF mutations have been widely described in melanomas and promote tumour progression and chemoresistance. We previously provided evidence that the HDAC inhibitor ITF2357 (Givinostat) targets oncogenic BRAF in SK-MEL-28 and A375 melanoma cells. Here, we show that oncogenic BRAF localises to the nucleus of these cells, and the compound decreases BRAF levels in both the nuclear and cytosolic compartments. Although mutations in the tumour suppressor p53 gene are not equally frequent in melanomas compared to BRAF, the functional impairment of the p53 pathway may also contribute to melanoma development and aggressiveness. To understand whether oncogenic BRAF and p53 may cooperate, a po…